So why is it that AZN did not choose to report the data and instead sanctioned NKTR to report the data albeit with restrictions as NKTR could say? I wonder if NktR not being able to answwer all the questions did not contribute to some of the uncertainty.
They DID say no signs of CV risk that isn't the issue on that front the unknown mindset of what the FDA views as adequate is the issue. NKTR threw the PR out there to stop the damage from SLXP (whether warranted or not). AZN allowed it but with limits since many scientific meeting require new data.